AstraZeneca has said it will appeal against last week’s decision by the National Institute for Health and Care Excellence (NICE) to recommend that its drug, Tagrisso, should not be used on England’s National Health Service as a first line treatment for a certain type of lung cancer.
NICE issued final guidance on 5 July saying that Tagrisso (osimertinib) was not an acceptable use of NHS resources for adults with untreated locally-advanced or metastatic epidermal growth factor receptor...